Subscribe to RSS
DOI: 10.1055/s-0029-1239518
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York
Nocturnal Blood Glucose and IGFBP-1 Changes in Type 1 Diabetes: Differences in the Dawn Phenomenon between Insulin Regimens
Publication History
received 14.06.2009
first decision 05.08.2009
accepted 24.08.2009
Publication Date:
15 October 2009 (online)

Abstract
Objective: Insulin-like growth factor binding protein-1 (IGFBP-1) is known to regulate the bioavailability of insulin-like growth factor (IGF) and the levels of IGFBP-1 are increased in the morning in patients with type 1 diabetes mellitus. We investigated the nocturnal fluctuations of glucose, IGFBP-1, and free IGF-1 levels with three insulin regimens.
Research Design and Methods: Forty-eight type 1 diabetes patients were divided into three groups according to their basal insulin therapy (continuous subcutaneous insulin infusion [CSII], insulin glargine, NPH insulin). Blood samples were obtained every 2 h between 2 300 h and 0700 h to measure plasma glucose, IGFBP-1 and free IGF-1 levels.
Results: The dawn phenomenon was more frequent with NPH (62.1%) than with glargine (16.6%, p<0.05) and CSII (14.3%, p<0.05). In the NPH group, the serum IGFBP-1 levels were markedly increased from 21.0±3.6 ng/ml at 2 300 h to 200.3±21.8 ng/ml at 0700 h and free IGF-1 levels were inversely decreased; these changes were partially suppressed in the CSII and glargine groups.
Conclusions: The use of insulin regimens that provide sufficient insulin levels in the early morning can suppress the dawn phenomenon, leading to improved glycemic control. The increase in circulating IGFBP-1 in the morning, as a result of waning of insulin action, lowers free IGF-1 levels and may cause insulin resistance.
Key words
insulin-like growth factor binding protein-1 - dawn phenomenon - type 1 diabetes mellitus
References
- 1
Dunger DB, Regan FM, Acerini CL.
Childhood and adolescent diabetes.
Endocr Dev.
2005;
9
107-120
MissingFormLabel
- 2
Frystyk J, Nyholm B, Skjaerbaek C. et al .
The circulating IGF system and its relationship with 24 h glucose regulation and insulin
sensitivity in healthy subjects.
Clin Endocrinol.
2003;
58
777-784
MissingFormLabel
- 3
Hilding A, Brismar K, Degerblad M. et al .
Altered relation between circulating levels of insulin-like growth factor-binding
protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic
patients compared to that in healthy subjects.
J Clin Endocrinol Metab.
1995;
80
2646-2652
MissingFormLabel
- 4
Kobayashi K, Amemiya S, Sawanobori E. et al .
Role of IGF binding protein-1 in the dawn phenomenon and glycemic control in children
and adolescents with IDDM.
Diabetes Care.
1997;
20
1442-1447
MissingFormLabel
- 5
Lang CH, Vary TC, Frost RA.
Acute in vivo elevation of insulin-like growth factor (IGF) binding protein-1 decreases
plasma free IGF-I and muscle protein synthesis.
Endocrinology.
2003;
144
3922-3933
MissingFormLabel
- 6
Inokuchi M, Hasegawa T, Anzo M. et al .
Standardized centile curves of body mass index for Japanese children and adolescents
based on the 1978–1981 national survey data.
Ann Hum Biol.
2006;
33
444-453
MissingFormLabel
- 7
Le Floch JP, Lévy M, Mosnier-Pudar H. et al .
Assessment of Detemir Administration in Progressive Treat-to-Target Trial (ADAPT)
Study Group. Comparison of once- versus twice-daily administration of insulin detemir,
used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment
of detemir administration in a progressive treat-to-target trial (ADAPT).
Diabetes Care.
2009;
32
32-37
MissingFormLabel
- 8
Lee PD, Giudice LC, Conover CA. et al .
Insulin-like growth factor binding protein-1: Recent findings and new directions.
Proc Soc Exp Biol Med.
1997;
216
319-357
MissingFormLabel
- 9
Perriello G, De Feo P, Torlone E. et al .
Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent)
diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin
in the absence of insulin waning.
Diabetologia.
1990;
33
52-59
MissingFormLabel
- 10
Pickup J, Keen H.
Continuous subcutaneous insulin infusion at 25 years: Evidence base for the expanding
use of insulin pump therapy in type 1 diabetes.
Diabetes Care.
2002;
25
593-598
MissingFormLabel
- 11
Pickup JC, Renard E.
Long-acting insulin analogs versus insulin pump therapy for the treatment of type
1 and type 2 diabetes.
Diabetes Care.
2008;
31
((Suppl 2))
S140-S145
MissingFormLabel
- 12
Rosenstock J, Park G, Zimmerman J.
U. S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group
.
Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes
on multiple daily insulin regimens. U. S. Insulin Glargine (HOE 901) Type 1 Diabetes
Investigator Group.
Diabetes Care.
2000;
23
1137-1142
MissingFormLabel
- 13
Schmidt MI, Hadji-Georgopoulos A, Rendell M. et al .
The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday
blood glucose variation.
Diabetes Care.
1981;
4
579-585
MissingFormLabel
- 14
van Cauter E, Desir D, Decoster C. et al .
Nocturnal decrease in glucose tolerance during constant glucose infusion.
J Clin Endocrinol Metab.
1989;
69
604-611
MissingFormLabel
Correspondence
H. YagasakiMD
Department of Pediatrics
Faculty of Medicine University of Yamanashi
1110 Shimokato, Chuo
409-3898 Yamanashi
Japan
Phone: +81 55-273-9606
Fax: +81 55-273-6745
Email: yagasaki@mwd.biglobe.ne.jp